Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

How Bone is Made in Children Receiving Dialysis

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2013 by University of California, Los Angeles.
Recruitment status was:  Recruiting
Children's Hospital Los Angeles
Loma Linda University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
Isidro Salusky, MD, University of California, Los Angeles Identifier:
First received: February 20, 2013
Last updated: February 22, 2013
Last verified: February 2013
The study outlined is designed to measure and to determine whether the combined use of vitamin D2 (ergocalciferoI) and 1-alpha-hydroxyvitamin D2 (doxercalciferol)) or doxercalciferol alone will correct the mineralization defect in pediatric patients with established secondary hyperparathyroidism (2°HPT) undergoing regular peritoneal dialysis. Serum phosphorus levels will be controlled with a calcium¬-free-metal free phosphate binder; (obtained at baseline and after 8 months of treatment) sevelamer. Indices of bone mineralization obtained at baseline and after 8 months of treatment will be measured by quantitative histomorphometry in iliac crest bone biopsies after double tetracycline labeling. Immunohistochemistry will be done in specimens of bone biopsies from iliac crest to examine the expression for selected markers of bone turnover and mineralization such as FGF-23, DMP1, MEPE and OPG. Serum PTH levels will be measured with the 1st and 2nd generation immunometric assay (PTH-IMAs) and fibroblast growth factor-23 (FGF-23) will be determined by one assay with specific detection antibodies that are against epitopes within the C-terminus of FGF-23 and another assay that uses antibodies against epitopes within the N- and C-terminal portions of the molecule respectively. The value of non-invasive assessment of bone mass by quantitative computed tomography (QCT) and its relationship with vascular disease determined by ultrasound (US) of intimal carotid thickness (CIMT) will be correlated with bone histomorphometry and the different biochemical determinations.

Condition Intervention Phase
Bone Mineralization Defect
Drug: Vitamin D2
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Regulation of Bone Mineralization in Renal Osteodystrophy

Resource links provided by NLM:

Further study details as provided by University of California, Los Angeles:

Primary Outcome Measures:
  • Improvement of bone mineralization defect demonstrated by bone histomorphometry [ Time Frame: 8 months ]
    Iliac crest bone biopsy pre and post treatment with vitamin D2

Secondary Outcome Measures:
  • Radiographic improvement of skeletal abnormalities associated with renal osteodystrophy [ Time Frame: 8 months ]
    We will compare skeletal lesions identified through radiographic studies with bone histomorphometry pre and post treatment with vitamin D2

Estimated Enrollment: 60
Study Start Date: March 2009
Estimated Study Completion Date: June 2014
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Treatment with vitamin D2
Vitamin D2 50,000u titrated to serum 25(OH)D values given orally once a month in addition to standard of care: Doxercalciferol escalating doses beginning at 2.5 mcg given orally thrice weekly. Sevelamer Carbonate 800 mg (1600- 4800 mg) given orally with each meal
Drug: Vitamin D2
These patients will receive standard of care vitamin D 1,25 therapy with intervention of vitamin D2
Other Name: Ergocalciferol
No Intervention: Standard of Care
Standard of Care: Doxercalciferol escalating doses beginning at 2.5 mcg given orally thrice weekly. Sevelamer Carbonate 800 mg (1600- 4800 mg) given orally with each meal


Ages Eligible for Study:   6 Years to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • medically stable patients
  • 6-21 years old
  • undergoing treatment with continuous cycling peritoneal dialysis
  • evidence of mineralization defect and secondary hyperparathyroidism

Exclusion Criteria:

  • histopathological lesion of bone such as adynamic bone or osteomalacia
  • poor compliance
  • current treatment with prednisone or other immunosuppressives
  • treatment with human recombinant growth hormone
  • parathyroidectomy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01799317

Contact: Isidro Salusky, MD 310.206.6987

United States, California
Loma Linda University Recruiting
Loma Linda, California, United States, 92354
Contact: Shobbha Sahney, MD    909-558-8242   
Principal Investigator: Shobha Sahney, MD         
Childrens Hospital Los Angeles Recruiting
Los Angeles, California, United States, 90027
Contact: Kevin Lemley, MD    323-361-2295   
Principal Investigator: Kevin Lemley, MD         
Sponsors and Collaborators
University of California, Los Angeles
Children's Hospital Los Angeles
Loma Linda University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigator: Isidro Salusky, MD University of California, Los Angeles
  More Information

Responsible Party: Isidro Salusky, MD, Principal Investigator, University of California, Los Angeles Identifier: NCT01799317     History of Changes
Other Study ID Numbers: IBS-05
R01DK035423-19 ( US NIH Grant/Contract Award Number )
Study First Received: February 20, 2013
Last Updated: February 22, 2013

Additional relevant MeSH terms:
Calcium Metabolism Disorders
Metabolic Diseases
Vitamin D
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents processed this record on May 25, 2017